Navigation Links
Agendia Receives €1.27 Million in Funding from the EU's Seventh Framework Programme

IRVINE, California and AMSTERDAM, July 21, 2011 /PRNewswire/ --


Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums. The partnerships will collectively receive nearly €12 million in funding from the European Union's 7th Framework Programme over a five-year term. Agendia, in particular, will receive €1.27 million for the development of new molecular diagnostics to help guide individualized treatment of cancer patients.

Both consortiums will be focused on gaining deeper insight into molecular subtypes of breast and colon cancer, and the development of biomarkers for use in predicting patients' individual responses to new targeted drugs. While RATHER seeks to improve treatment for triple negative and lobular breast cancer patients, COLTHERES is focused on response or resistance to targeted therapeutics in colon cancer. Both consortiums consist of clinical partners as well as leading translational research groups with a proven track record in developing companion diagnostics for cancer therapies. The objective of these partnerships is to define and perform biomarker-driven clinical trials to improve cancer therapy outcomes, with Agendia developing reliable and standardized biomarker tests.

Other members of the consortiums include the University College Dublin, the Netherlands Cancer Institute (NKI) Amsterdam, Institute Curie Paris, Malmö University Hospital Lund, Vall d'Hebron Barcelona, University of Cambridge, OncoMark Ltd Dublin, University of Leuven, Niguarda Ca' Granda Hospital Milano, IDIBELL Barcelona, Horizon Discovery UK, University of Liverpool, Swiss Institute of Bioinformatics and the University of Torino School of Medicine.

"We are pleased to participate in these EU funded projects and to work with these outstanding international experts in the fields of functional genomics, pharmacogenetics, bio-informatics and clinical oncology," said Prof. Dr. Rene Bernards, CSO of Agendia. "For Agendia, this is a great opportunity to develop new companion diagnostics together with a large group of scientists and physicians to address urgent clinical needs. The unique consortium structures will allow a rapid translation of results from research and discovery into a clinical setting that benefits patients."

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and who can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States. For more information, please visit

For more information on COLTHERES consortium go to For more information on the RATHER Project go to

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
2. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
3. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
4. FDA Broadens Clearance for Agendias MammaPrint(R)
5. /C O R R E C T I O N -- Agendia B.V./
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
10. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
11. Agendia Launches TargetPrint(R) for Breast Cancer Patients
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
(Date:11/30/2015)... Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ... Breast Care to increase collaboration with sub-specialists around the ... --> Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ...
(Date:11/29/2015)... Nov. 29, 2015 CIVCO Medical Solutions ... at the Radiological Society of North ... Chicago November 29 – December 4, ... to offer customers unrivaled versatility, enhanced user experience ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... CHICAGO, IL November 30, 2015 (PRWEB) , ... ... ... SpeechCheck and Winscribe are pleased to announce their strategic partnership at ... speech recognition consultants, SpeechCheck, Inc., and Winscribe, global providers of cutting-edge dictation ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... 2016. In 2016, expected coding changes are likely to include new codes for ... It’s not easy to understand the effects of code changes in musculoskeletal, radiology ...
(Date:11/30/2015)... ... ... today announced the introduction of three Nightstick® brand LED traffic wands with an average retail ... NSP-1632 ), yellow ( NSP-1634 ) and blue ( NSP-1636 ), the SL-1600 series LED ... in blinking strobe mode using a fresh set of 3 AAA cells (included). , Built ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... available today from the new company, Sublime Beauty NATURALS®. All products are available ... natural products, like essential oils, organic facial serums and USDA Certified Organic Sesame ...
(Date:11/29/2015)... ... November 29, 2015 , ... "I struggled for years with pain ... Mother and Wife would love to do, I missed. We moved back home from ... call Dr. Zaidan first. They have changed my life drastically. I love all of ...
Breaking Medicine News(10 mins):